Segment Reporting (Summary of Net Revenues by Product) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Revenues	$ 183,903	$ 174,414	$ 355,074	$ 344,942
Finished Pharmaceutical Products Segment
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Revenues	183,903	174,414	355,074	344,942
Finished Pharmaceutical Products Segment \| Glucagon
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Revenues	11,905	20,602	21,075	41,445
Finished Pharmaceutical Products Segment \| Primatene MIST
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Revenues	21,004	22,880	50,767	51,931
Finished Pharmaceutical Products Segment \| BAQSIMI
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Revenues	45,503	46,687	77,937	85,042
Finished Pharmaceutical Products Segment \| Epinephrine
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Revenues	15,854	16,180	35,067	34,767
Finished Pharmaceutical Products Segment \| Lidocaine
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Revenues	15,039	14,999	28,499	28,643
Finished Pharmaceutical Products Segment \| Ipratropium Bromide
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Revenues	8,411		8,411
Finished Pharmaceutical Products Segment \| Other Products
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Revenues	$ 66,187	$ 53,066	$ 133,318	$ 103,114